Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database

Fig. 1

Evolution of canakinumab posology in FMF patients: overall (A), in patients who initiated canakinumab after health authority approval (B), in adult patients (C) and in pediatric patients (D). (FMF: Familial Mediterranean Fever, HTA: Heath technology assessment; q4w: every 4 weeks; q5-7w: every 5 to 7 weeks; q8w: every 8 weeks)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us